Login

TC BioPharm (Holdings) plc

tcbiopharm.com

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2024 20-F, filed May 9, 2025. Its latest SEC filing is a 15-12G from Dec 3, 2025.

The sections below describe the company as of the FY2024 annual report.

What Did They Do?

Develops donor-derived immune-cell therapies intended to treat patients with cancers and viral infections.

Who Were Their Customers?

Partners fund or partly fund collaborative research and development, while physicians who participate in the company's clinical studies are described as future customers.

Who Did They Compete With?

Competes with AdicetBio, Allogene, Autolus, Gamma Delta Therapeutics, In8Bio, Novartis, Gilead, and Bristol Myers Squibb

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support